Participant flow

Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma · Source last updated 2020-01-13

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   RP6530 administered 200 mg orally twice a day.

   id

   FG000

   title

   Dose escalation_Cohort 1_200 mg

2. description

   RP6530 administered 400 mg orally twice a day.

   id

   FG001

   title

   Dose escalation_Cohort 2_400 mg

3. description

   RP6530 administered 800 mg orally twice a day under fasting condition

   id

   FG002

   title

   Dose escalation_Cohort 3_800 mg (Fasting)

4. description

   RP6530 administered 800 mg orally twice a day under fed condition

   id

   FG003

   title

   Dose escalation_Cohort 4_800 mg (Fed)

5. description

   RP6530 administered 800 mg orally twice a day under fasting condition

   id

   FG004

   title

   Dose expansion_PTCL_800 mg (Fasting)

6. description

   RP6530 administered 800 mg orally twice a day under fasting condition

   id

   FG005

   title

   Dose expansion_CTCL_800 mg (Fasting)

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         1

      2. group Id

         FG001

         num Subjects

         1

      3. group Id

         FG002

         num Subjects

         2

      4. group Id

         FG003

         num Subjects

         0

      5. group Id

         FG004

         num Subjects

         0

      6. group Id

         FG005

         num Subjects

         0

      type

      Premature discontinuation due to PD

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         4

      2. group Id

         FG001

         num Subjects

         4

      3. group Id

         FG002

         num Subjects

         5

      4. group Id

         FG003

         num Subjects

         6

      5. group Id

         FG004

         num Subjects

         19

      6. group Id

         FG005

         num Subjects

         20

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         3

      2. group Id

         FG001

         num Subjects

         3

      3. group Id

         FG002

         num Subjects

         3

      4. group Id

         FG003

         num Subjects

         6

      5. group Id

         FG004

         num Subjects

         19

      6. group Id

         FG005

         num Subjects

         20

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         1

      2. group Id

         FG001

         num Subjects

         1

      3. group Id

         FG002

         num Subjects

         2

      4. group Id

         FG003

         num Subjects

         0

      5. group Id

         FG004

         num Subjects

         0

      6. group Id

         FG005

         num Subjects

         0

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice